SCHEMBL739893

SCHEMBL739893

COc1cccc(C(C)(C)NC(=O)c2cc3c(NC(=O)c4cccs4)n[nH]c3s2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.48
NPC1 O15118 7/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KDM4E B2RXH2 7/20 0.46
MAPT P10636 6/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
TP53 P04637 3/20 0.41
NPSR1 Q6W5P4 5/20 0.41
POLB P06746 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
AURKA O14965 1/20 0.41
TDP1 Q9NUW8 3/20 0.40
ALDH1A1 P00352 4/20 0.40
HPGD P15428 3/20 0.40
LMNA P02545 3/20 0.40
MAPK1 P28482 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL741896 0.91 RAB9A (0.47) RAB9ANPC1SMN1; SMN2KDM4EMAPT
SCHEMBL743308 0.88 AURKA (0.48) RAB9ANPC1SMN1; SMN2KDM4EMAPT
SCHEMBL741526 0.88 RAB9A (0.41) RAB9ANPC1SMN1; SMN2KDM4EMAPT
SCHEMBL739810 0.85 APLNR (0.47) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL740599 0.84 AURKA (0.49) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL741356 0.84 KMT2A (0.43) RAB9ANPC1SMN1; SMN2KDM4EMAPT
SCHEMBL1779010 0.83 RXFP1 (0.48) RAB9ANPC1SMN1; SMN2KDM4EMAPT
SCHEMBL740517 0.82 AURKA (0.65) AURKAABL1
SCHEMBL2422290 0.82 ROCK2 (0.56) RAB9ANPC1SMN1; SMN2KDM4EMAPT
SCHEMBL741622 0.81 RAB9A (0.41) RAB9ANPC1SMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US claimed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed